Abstract
It has been estimated that greater than 35% of all human genes undergo alternative splicing. The process of alternative splicing is highly regulated and disruption of a splicing pattern can produce splice variants that have different functions. Certain splice variants that are associated with induction of cell death, regulation of cellular proliferation and differentiation, cell signaling, and angiogenesis are present in a variety of cancers. Several of these cancer-related alternatively spliced genes will be discussed in this review. In addition, alternative splicing is associated with several genetic disorders such as β-thalassemia, cystic fibrosis, and muscular dystrophy. Control of pre-mRNA splicing patterns with antisense oligonucleotides presents an attractive way to potentially treat and manage a variety of diseases. This review will discuss potential gene targets for antisense oligonucleotide induced modification of alternative splicing patterns. Furthermore, the chemistries and delivery strategies of antisense oligonucleotides will be discussed.
Current Cancer Drug Targets
Title: Modification of Alternative Splicing by Antisense Oligonucleotides as a Potential Chemotherapy for Cancer and Other Diseases
Volume: 1 Issue: 3
Author(s): D. R. Mercatante, P. Sazani and R. Kole
Affiliation:
Abstract: It has been estimated that greater than 35% of all human genes undergo alternative splicing. The process of alternative splicing is highly regulated and disruption of a splicing pattern can produce splice variants that have different functions. Certain splice variants that are associated with induction of cell death, regulation of cellular proliferation and differentiation, cell signaling, and angiogenesis are present in a variety of cancers. Several of these cancer-related alternatively spliced genes will be discussed in this review. In addition, alternative splicing is associated with several genetic disorders such as β-thalassemia, cystic fibrosis, and muscular dystrophy. Control of pre-mRNA splicing patterns with antisense oligonucleotides presents an attractive way to potentially treat and manage a variety of diseases. This review will discuss potential gene targets for antisense oligonucleotide induced modification of alternative splicing patterns. Furthermore, the chemistries and delivery strategies of antisense oligonucleotides will be discussed.
Export Options
About this article
Cite this article as:
D. R. Mercatante , P. Sazani and R. Kole , Modification of Alternative Splicing by Antisense Oligonucleotides as a Potential Chemotherapy for Cancer and Other Diseases, Current Cancer Drug Targets 2001; 1 (3) . https://dx.doi.org/10.2174/1568009013334124
DOI https://dx.doi.org/10.2174/1568009013334124 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome
Current Medicinal Chemistry Chromene, Quinoline Hybrids as Potential Anti-Cancer Agents: A Novel and Distinct Approach for the Synthesis of Quinoline Derivatives
Letters in Organic Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer
Current Pharmaceutical Design Editorial [ Pharmacological Modulation of Liver Ischemia - Reperfusion Injury Executive Editors: G.K. Glantzounis, D.P. Mikhailidis, A.M. Seifalian and B.R. Davidson ]
Current Pharmaceutical Design From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Current Medicinal Chemistry Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Cytotoxic Effect of the Combination of Gemcitabine and Atorvastatin Loaded in Nanoparticle on the MCF-7 Breast Cancer Cells and HFS Human Foreskin Cells
Current Nanoscience Analysis and Validation of Differentially Expressed MicroRNAs with their Target Genes Involved in GLP-1RA Facilitated Osteogenesis
Current Bioinformatics PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry SKINOMICS: Transcriptional Profiling in Dermatology and Skin Biology
Current Genomics The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design Malaria Heat Shock Proteins: Drug Targets that Chaperone other Drug Targets
Infectious Disorders - Drug Targets Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology A Guide to Treatment of Sarcoidosis
Current Drug Therapy